Alcobra Ltd. (ADHD) Downgraded by Stifel Nicolaus to “Hold”
Alcobra Ltd. (NASDAQ:ADHD) was downgraded by analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a report released on Friday, The Fly reports.
Several other research firms have also recently weighed in on ADHD. Piper Jaffray Cos. reissued an “overweight” rating and issued a $10.00 price objective on shares of Alcobra in a research report on Tuesday, August 30th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $16.00 target price on shares of Alcobra in a research report on Wednesday, August 31st. Jefferies Group reaffirmed a “buy” rating on shares of Alcobra in a research report on Thursday, August 25th. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Alcobra in a research report on Thursday, September 1st. Finally, WBB Securities cut Alcobra from a “hold” rating to a “sell” rating and reduced their target price for the stock from $5.00 to $4.00 in a research report on Monday, September 12th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company’s stock. Alcobra has an average rating of “Hold” and a consensus price target of $6.47.
Alcobra (NASDAQ:ADHD) traded up 2.115% during trading on Friday, hitting $2.655. 260,209 shares of the stock traded hands. The company has a 50-day moving average price of $4.41 and a 200 day moving average price of $4.46. The stock’s market cap is $73.18 million. Alcobra has a one year low of $1.95 and a one year high of $8.78.
Alcobra (NASDAQ:ADHD) last posted its quarterly earnings data on Tuesday, August 30th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.01. Analysts expect that Alcobra will post ($0.94) earnings per share for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Fund Advisors raised its stake in shares of Alcobra by 1.8% in the second quarter. BlackRock Fund Advisors now owns 361,130 shares of the company’s stock worth $1,621,000 after buying an additional 6,516 shares during the period. Stifel Financial Corp raised its stake in shares of Alcobra by 34.2% in the second quarter. Stifel Financial Corp now owns 62,000 shares of the company’s stock worth $278,000 after buying an additional 15,800 shares during the period. Palo Alto Investors LLC raised its stake in shares of Alcobra by 7.3% in the second quarter. Palo Alto Investors LLC now owns 272,788 shares of the company’s stock worth $1,225,000 after buying an additional 18,600 shares during the period. Jefferies Group LLC acquired a new stake in shares of Alcobra during the second quarter worth $533,000. Finally, VHCP Management LLC raised its stake in shares of Alcobra by 28.7% in the second quarter. VHCP Management LLC now owns 623,313 shares of the company’s stock worth $2,799,000 after buying an additional 138,813 shares during the period. Hedge funds and other institutional investors own 73.69% of the company’s stock.
Alcobra Company Profile
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.